PALISADE BIO, INC. (PALI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 200K 400K 600K Q2 '14: 14.2K Q3 '14: 16.7K Q4 '14: 18.8K Q1 '15: 17.6K Q2 '15: 15.1K Q3 '15: 12.6K Q2 '16: 10K Q3 '16: 10K Q4 '16: 16.2K Q1 '17: 16.2K Q2 '17: 16.2K Q3 '17: 16.2K Q4 '17: 260K Q1 '18: 260K Q2 '18: 510K Q3 '18: 510K Q4 '18: 260K Q1 '19: 260K Q2 '19: 15.4K Q3 '19: 15.4K Q4 '19: 15.4K Q1 '20: 18.9K Q2 '20: 13.5K Q3 '20: 13.5K Q4 '20: 13.5K Q4 '22: 0 Q1 '23: 250K Q2 '23: 250K Q3 '23: 250K Q4 '23: 250K Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 500K Q2 '15 Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '16: -19.3M Q4 '16: -20.6M Q1 '17: -18.6M Q2 '17: -19M Q3 '17: -16.7M Q4 '17: -13.3M Q1 '18: -11.4M Q2 '18: -9.2M Q3 '18: -8.7M Q4 '18: -8.3M Q1 '19: -8.4M Q2 '19: -8.3M Q3 '19: -8.3M Q4 '19: -8.6M Q1 '20: -8.2M Q2 '20: -8.1M Q3 '20: -7.8M Q4 '20: -8.9M Q1 '21: -8.9M Q2 '21: -39.9M Q3 '21: -41.1M Q4 '21: -41.9M Q1 '22: -43.8M Q2 '22: -14.5M Q3 '22: -15.9M Q4 '22: -15.7M Q1 '23: -14.4M Q2 '23: -14.4M Q3 '23: -13.8M Q4 '23: -13.1M Q1 '24: -14.2M Q2 '24: -14.8M Q3 '24: -14.6M Q4 '24: -14.9M Q1 '25: -13.5M Q2 '25: -12.1M Q3 '25: -11.5M Q4 '25: -18.1M Q1 '26: -26.5M Q2 '26: -35.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '16: -20.4M Q4 '16: -21.1M Q1 '17: -22M Q2 '17: -22.8M Q3 '17: -17.7M Q4 '17: -15.7M Q1 '18: -10.2M Q2 '18: -6.2M Q3 '18: -7.9M Q4 '18: -4.9M Q1 '19: -5.9M Q2 '19: -6.7M Q3 '19: -6.6M Q4 '19: -8.4M Q1 '20: -7.6M Q2 '20: -8M Q3 '20: -8.1M Q4 '20: -10.3M Q1 '21: -12M Q2 '21: -41.9M Q3 '21: -31.9M Q4 '21: -26.6M Q1 '22: -26.8M Q2 '22: 2.6M Q3 '22: -9.5M Q4 '22: -14.3M Q1 '23: -12.4M Q2 '23: -13.4M Q3 '23: -13M Q4 '23: -12.3M Q1 '24: -13.5M Q2 '24: -14.2M Q3 '24: -14.1M Q4 '24: -14.4M Q1 '25: -13.1M Q2 '25: -11.8M Q3 '25: -11.2M Q4 '25: -16.8M Q1 '26: -24.2M Q2 '26: -31.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q3 '16: -15.4M Q4 '16: -15.6M Q1 '17: -16.6M Q2 '17: -16.4M Q3 '17: -15.2M Q4 '17: -13.4M Q1 '18: -10.8M Q2 '18: -10M Q3 '18: -8.3M Q4 '18: -7.7M Q1 '19: -7.5M Q2 '19: -6.6M Q3 '19: -6.9M Q4 '19: -7.3M Q1 '20: -7.3M Q2 '20: -6.3M Q3 '20: -5.3M Q4 '20: -4.8M Q1 '21: -4.3M Q2 '21: -11.4M Q3 '21: -13.3M Q4 '21: -14.8M Q1 '22: -17.3M Q2 '22: -12.8M Q3 '22: -13.1M Q4 '22: -13.4M Q1 '23: -13.1M Q2 '23: -12.1M Q3 '23: -11.7M Q4 '23: -11.1M Q1 '24: -10.8M Q2 '24: -12.1M Q3 '24: -12.6M Q4 '24: -12.2M Q1 '25: -11.3M Q2 '25: -9.7M Q3 '25: -10.1M Q4 '25: -10.8M Q1 '26: -12.4M Q2 '26: -18.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q2 '11: -9.8M Q3 '11: -9.3M Q4 '11: -8.3M Q1 '12: -8.1M Q2 '12: -8.2M Q3 '12: -7.8M Q4 '12: -8.5M Q1 '13: -8.9M Q2 '13: -9.8M Q3 '13: -10.8M Q4 '13: -10.7M Q1 '14: -11M Q2 '14: -10.1M Q3 '14: -10.9M Q4 '14: -11.9M Q1 '15: -13.8M Q2 '15: -16.3M Q3 '15: -18.7M Q4 '15: -19.1M Q1 '16: -17.9M Q2 '16: -16.6M Q3 '16: -15.6M Q4 '16: -15.7M Q3 '11 Q2 '12 Q1 '13 Q4 '13 Q3 '14 Q2 '15 Q1 '16 Q4 '16

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q3 '16: 8.8M Q3 '17: 14.2M Q3 '18: 15.2M Q2 '20: 2.8M Q3 '20: 2.8M Q2 '21: 9M Q3 '21: 12.1M Q1 '22: 324.5K Q2 '22: 405.9K Q3 '22: 974.2K Q1 '23: 287.7K Q2 '23: 427.9K Q3 '23: 489.6K Q1 '24: 768.1K Q2 '24: 1.2M Q3 '24: 1.5M Q1 '25: 4.8M Q2 '25: 4.8M Q3 '25: 7.5M Q1 '26: 209.7M Q2 '26: 211.4M Q3 '18 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-210.00 -140.00 -70.00 0.00 70.00 140.00 210.00 Q1 '15: -0.25 Q2 '15: -0.23 Q3 '15: -0.24 Q2 '16: -1.51 Q3 '16: -2.04 Q4 '16: -4.37 Q1 '17: -4.12 Q2 '17: -4.04 Q3 '18: -1.04 Q4 '18: -2.55 Q1 '19: -5.83 Q2 '19: -6.45 Q3 '19: -6.92 Q4 '19: -3.80 Q1 '20: -5.96 Q2 '20: -5.18 Q3 '20: -5.25 Q4 '20: -8.44 Q1 '21: -3.65 Q2 '21: -7.08 Q3 '21: -6.00 Q4 '21: -170.08 Q1 '22: -182.25 Q2 '22: -183.92 Q3 '22: -188.44 Q4 '22: -16.53 Q1 '23: -11.70 Q2 '23: -13.86 Q3 '23: -17.14 Q4 '23: -27.21 Q1 '24: -23.67 Q2 '24: -19.06 Q3 '24: -14.00 Q4 '24: -10.92 Q1 '25: -6.80 Q2 '25: -4.06 Q3 '25: -2.12 Q4 '25: -0.30 Q1 '26: 0.12 Q2 '26: 0.65 Q3 '16 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.